Karyopharm Therapeutics Inc. (KPTI): Debt Offering News

Key Facts Surrounding This News Item


  • KPTI had a POWR Rating of D (Sell) coming into today.
  • KPTI was -20.70% below its 10-Day Moving Average coming into today.
  • KPTI was -26.91% below its 20-Day Moving Average coming into today.
  • KPTI was -30.94% below its 50-Day Moving Average coming into today.
  • KPTI was -31.23% below its 100-Day Moving Average coming into today.
  • KPTI was -22.00% below its 200-Day Moving Average coming into today.
  • KPTI had returned +29.53% year-to-date leading up to today’s news, versus a 0.00% return from the benchmark S&P 500 during the same period.

More Info About Karyopharm Therapeutics Inc. (KPTI)


Karyopharm Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company was founded in 2008 and is based in in Newton, Massachusetts. View our full KPTI ticker page with ratings, news, and more.

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Top Stories on StockNews.com

NASDAQ: INTU | Intuit Inc. News, Ratings, and Charts

Intuit (INTU) issues guidance following U.S. tax season, stock falls

Intuit Inc. INTU, -5.25% stock fell roughly 5% in after-hours trading Thursday.
NASDAQ: SBUX | Starbucks Corporation News, Ratings, and Charts

Starbucks (SBUX) reports Q2 earnings, raises forecast

The company beat earnings expectations and raised its full-year profit forecast.
NYSE: F | Ford Motor Company Common Stock News, Ratings, and Charts

Ford (F) reports Q1 earnings, shares jump

Ford Motor Co. stock rose more than 7% in the extended session Thursday after the carmaker reported first-quarter earnings.
NASDAQ: AMZN | Amazon.com, Inc. News, Ratings, and Charts

Amazon (AMZN) reports Q1 earnings, beats estimates

Amazon reported a huge beat on profits and matched estimates for revenue in its first-quarter earnings results.
NASDAQ: INTC | Intel Corporation News, Ratings, and Charts

Intel (INTC) reports earnings, stock plunges

In first earnings report as permanent CEO, Bob Swan says ‘we expect market conditions to improve in the second half’.

Read More Stories


More Karyopharm Therapeutics Inc. (KPTI) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All KPTI News
Page generated in 1.1989 seconds.